December 9, 2020
LONDON (Reuters) -Britain’s medicine regulator has advised that people with a history of significant allergic reactions do not get Pfizer-BioNTech’s COVID-19 vaccine after two people reported adverse effects on the first day of rollout.
Britain began mass vaccinating its population on Tuesday in a global drive that poses one of the biggest logistical challenges in peacetime history, starting with the elderly and frontline workers
National Health Service medical director Stephen Powis said the advice had been changed after two NHS workers reported anaphylactoid reactions associated with getting the shot.
“As is common with new vaccines the MHRA (regulator) have advised on a precautionary basis that people with a significant history of allergic reactions do not receive this vaccination, after two people with a history of significant allergic reactions responded adversely yesterday,” Powis said.
“Both are recovering well.”
The Medicines and Healthcare products Regulatory Agency (MHRA) said the advice to healthcare professionals was “precautionary”, and MHRA Chief Executive June Raine said that the reaction was not a side-effect observed in trials.
“Last evening, we were looking at two case reports of allergic reactions. We know from the very extensive clinical trials that this wasn’t a feature,” she told lawmakers.
Pfizer UK and BioNTech were not immediately available for comment.
(Reporting by Alistair Smout; additional reporting by Josephine Mason and Patricia Weiss, Editing by Paul Sandle)
